Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 9,945 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Single-arm Clear all

Conditions: Generalized Myasthenia Gravis, gMG
Interventions: Efgartigimod IV or Efgartigimod PH20 SC; Biological
Lead sponsor: argenx; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 3
States / cities: Chicago, Illinois • Charlotte, North Carolina • Charlottesville, Virginia

Conditions: Multiple Myeloma
Interventions: Panobinostat Capsules, Bortezomib Injection, Dexamethasone tablets; Drug
Lead sponsor: pharmaand GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 9
States / cities: Fayetteville, Arkansas • Los Angeles, California • Fort Collins, Colorado + 6 more

Conditions: Alzheimer Disease
Interventions: memantine; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 50 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Distal Aortic Dissection, Dissection, Aortic Acute, Acute Type B Aortic Dissection (Uncomplicated)
Interventions: BMT+TEVAR, BMT; Device · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Lymphedema, Lymphedema Arm, Lymphedema of Upper Arm
Interventions: LymphaVibe; Device
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Systemic Lupus Erythematosus Arthritis
Interventions: Methylprednisolone, Placebos; Drug
Lead sponsor: Oklahoma Medical Research Foundation; Other
Eligibility: 18 Years to 70 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Inferior Alveolar Nerve Injury, Nerve Injury, Neurosensory Disorder, Mandibular Nerve Injury
Interventions: Platelet-rich fibrin (PRF), Proximal segment grooving (PSG); Procedure
Lead sponsor: Jesse Han; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Interventions: MEDI-573, Aromatase Inhibitor; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 34
States / cities: Scottsdale, Arizona • Bakersfield, California • Pleasant Hill, California + 28 more

Conditions: Heart Failure
Interventions: Implantable Hemodynamic Monitor (Chronicle® IHM), and IHM in combination with single chamber ICD (Chronicle ICD); Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 442 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 52
States / cities: Birmingham, Alabama • La Jolla, California • Loma Linda, California + 43 more

Conditions: Ulcerative Colitis
Interventions: IV Tulisokibart, IV Placebo, SC Tulisokibart, SC Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 1,109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 76
States / cities: Dothan, Alabama • Fairhope, Alabama • Litchfield Park, Arizona + 65 more

Conditions: Opioid-Related Disorders
Interventions: Placebo taken first, Generic H/A taken first, Vycavert taken first, Generic H/A plus i taken first, Generic H/A plus p taken first; Drug
Lead sponsor: Acura Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: B-Cell Chronic Lymphocytic Leukemia
Interventions: CNF2024 (BIIB021); Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: San Diego, California • New York, New York • Houston, Texas

Conditions: Lumbar Spine Injury, Spinal Fusion, Frailty, Prehabilitation, Nutritional Supplementation, Functional Outcome
Interventions: Multimodal Prehabilitation, Standard Pre-Surgical Clinical Care; Other
Lead sponsor: University of Florida; Other
Eligibility: 55 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Anesthesia
Interventions: Dexmedetomidine; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 3 Years to 18 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Essential Tremor of the Upper Limbs
Interventions: IncobotulinumtoxinA, Placebo; Drug
Lead sponsor: Merz Pharmaceuticals GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Colon Cancer, dMMR Colorectal Cancer
Interventions: Dostarlimab; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 2
States / cities: Iowa City, Iowa • Madison, Wisconsin

Conditions: Acute Respiratory Infections, Acute Rhinosinusitis
Interventions: Acetaminophen, Amoxicillin, Dextromethorphan hydrobromide with guaifenesin, Guaifenesin, Pseudoephedrine Sustained Action, Saline spray (0.65%); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Lung Cancer
Interventions: Intraoperative ultrasound; Device
Lead sponsor: Joel Thompson, PhD; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Ewing's Family Tumors, Renal Tumors, Hepatoblastoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Primary Malignant Brain Neoplasms, Retinoblastoma, Medulloblastoma, Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET), Atypical Teratoid/Rhabdoid Tumor (AT/RT), CNS Tumors, Germ Cell Tumors
Interventions: Ifosfamide, Etoposide, Mesna, G-CSF, Busulfan, Melphalan, Thiotepa, Autologous stem cell infusion, Radiation, Carboplatin, Paclitaxel, Leukapheresis, Anti-seizure prophylaxis, Ursodiol; Drug · Biological · Radiation + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 70 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, placebo, glimepiride; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions: VV-14295; Genetic
Lead sponsor: Kriya Therapeutics, Inc.; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Erie, Pennsylvania

Conditions: Head and Neck Cancer, Oropharynx Cancer, Oropharyngeal Squamous Cell Carcinoma
Interventions: Intensity modulated radiotherapy (IMRT)/volumetric modulated arc therapy (VMAT) or Pencil beam proton therapy (PBPT); Radiation
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 6
States / cities: Baltimore, Maryland • Bel Air, Maryland • Columbia, Maryland + 1 more

Conditions: Alcohol Use Disorder With Insomnia
Interventions: Cognitive Behavioral Therapy for Insomnia, Sleep Hygiene Education; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Coatesville, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Prosthetic Joint Infection of Knee
Interventions: Intervention 1: Alternating Magnetic Field Treatment, Intervention 2 - Sham Treatment, Debridement, Antibiotics, Implant Retention; Device · Procedure
Lead sponsor: Solenic Medical, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: New Albany, Ohio • Tulsa, Oklahoma

Search by objective public record fields.

Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis

Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease

ACute Uncomplicated Type b Aortic Dissection: Endovascular Repair vs. Best Medical Therapy

Clinical Evaluation of a Device for Treatment of Lymphedema of the Upper Extremity

MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE

Platelet-rich Fibrin and Grooving for Sagittal Split Osteotomy

Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer

Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (HF) (REDUCEhf)

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users

Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL

Does Prehabilitation Improve Outcomes in Patients Undergoing Complex Spine Fusion Surgery?

Effect of Dexmedetomidine of Gastrointestinal Motility

Botulinum Toxin A to Treat Arm Tremor

Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers

Treatment of Acute Sinusitis

Thoracoscopic Lung Cancer Staging With the Use of Intraoperative Ultrasound

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus

A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration

Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110)

CBT-I Augmentation of Medication for Drinking in AUD

Sola2 AMF Knee System Added to Surgery and Antibiotics in Adults With Knee Implant Infection